Afficher la couverture 'Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) | Bergmeijer, Thomas' en grand format
/5

0 avis

Consulter en ligne

Suggestions

Du même auteur

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

Archive ouverte | Bergmeijer, Thomas | CCSD

International audience. The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel sh...

Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.

Archive ouverte | Reny, Jean-Luc | CCSD

International audience. Prior studies have shown an association between high on-clopidogrel platelet reactivity (PR) and the risk of major adverse cardiovascular events (MACE). However, large intervention trials on ...

International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies

Archive ouverte | Angiolillo, Dominick | CCSD

International audience

Chargement des enrichissements...